Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer DrugBenzinga • 06/05/25
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda BiosimilarZacks Investment Research • 06/05/25
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 millionGlobeNewsWire • 06/05/25
Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary sharesGlobeNewsWire • 06/04/25
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®GlobeNewsWire • 06/04/25
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NYGlobeNewsWire • 06/02/25
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in EuropeGlobeNewsWire • 05/28/25
Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq StockholmGlobeNewsWire • 05/16/25
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq StockholmGlobeNewsWire • 05/08/25
Alvotech Reports Results for the First Quarter of 2025 and Provides Business UpdateGlobeNewsWire • 05/07/25
Alvotech Reports Results for the First Quarter of 2025 and Provides Business UpdateGlobeNewsWire • 05/07/25
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025GlobeNewsWire • 05/07/25
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)GlobeNewsWire • 05/02/25
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDTGlobeNewsWire • 05/02/25